Join
Live feed
·
INSIDERFilingvia Quantisnow
Rhythm Pharmaceuticals Inc. logo

Chief Scientific Officer Garfield Alastair sold $912,703 worth of shares (7,763 units at $117.57) as part of a pre-agreed trading plan, decreasing direct ownership by 77% to 2,295 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RYTM· Rhythm Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RYTM (Rhythm Pharmaceuticals Inc.) and more on Quantisnow.